Titre : Anomalies du tube neural

Anomalies du tube neural : Questions médicales fréquentes

Termes MeSH sélectionnés :

Early Detection of Cancer
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Anomalies du tube neural : Questions médicales les plus fréquentes", "headline": "Anomalies du tube neural : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Anomalies du tube neural : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-16", "dateModified": "2025-03-13", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Anomalies du tube neural" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Malformations du système nerveux", "url": "https://questionsmedicales.fr/mesh/D009421", "about": { "@type": "MedicalCondition", "name": "Malformations du système nerveux", "code": { "@type": "MedicalCode", "code": "D009421", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C16.131.666" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Anencéphalie", "alternateName": "Anencephaly", "url": "https://questionsmedicales.fr/mesh/D000757", "about": { "@type": "MedicalCondition", "name": "Anencéphalie", "code": { "@type": "MedicalCode", "code": "D000757", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C16.131.666.680.196" } } }, { "@type": "MedicalWebPage", "name": "Malformation d'Arnold-Chiari", "alternateName": "Arnold-Chiari Malformation", "url": "https://questionsmedicales.fr/mesh/D001139", "about": { "@type": "MedicalCondition", "name": "Malformation d'Arnold-Chiari", "code": { "@type": "MedicalCode", "code": "D001139", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C16.131.666.680.291" } } }, { "@type": "MedicalWebPage", "name": "Myéloméningocèle", "alternateName": "Meningomyelocele", "url": "https://questionsmedicales.fr/mesh/D008591", "about": { "@type": "MedicalCondition", "name": "Myéloméningocèle", "code": { "@type": "MedicalCode", "code": "D008591", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C16.131.666.680.610" } } }, { "@type": "MedicalWebPage", "name": "Pentalogie de Cantrell", "alternateName": "Pentalogy of Cantrell", "url": "https://questionsmedicales.fr/mesh/D058502", "about": { "@type": "MedicalCondition", "name": "Pentalogie de Cantrell", "code": { "@type": "MedicalCode", "code": "D058502", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C16.131.666.680.705" } } }, { "@type": "MedicalWebPage", "name": "Dysraphie spinale", "alternateName": "Spinal Dysraphism", "url": "https://questionsmedicales.fr/mesh/D016135", "about": { "@type": "MedicalCondition", "name": "Dysraphie spinale", "code": { "@type": "MedicalCode", "code": "D016135", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C16.131.666.680.800" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Spina bifida cystica", "alternateName": "Spina Bifida Cystica", "url": "https://questionsmedicales.fr/mesh/D016137", "about": { "@type": "MedicalCondition", "name": "Spina bifida cystica", "code": { "@type": "MedicalCode", "code": "D016137", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C16.131.666.680.800.730" } } }, { "@type": "MedicalWebPage", "name": "Spina bifida occulta", "alternateName": "Spina Bifida Occulta", "url": "https://questionsmedicales.fr/mesh/D016136", "about": { "@type": "MedicalCondition", "name": "Spina bifida occulta", "code": { "@type": "MedicalCode", "code": "D016136", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C16.131.666.680.800.750" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Anomalies du tube neural", "alternateName": "Neural Tube Defects", "code": { "@type": "MedicalCode", "code": "D009436", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Richard H Finnell", "url": "https://questionsmedicales.fr/author/Richard%20H%20Finnell", "affiliation": { "@type": "Organization", "name": "Department of Molecular and Human Genetics and Medicine, Center for Precision Environmental Health, Baylor College of Medicine, Houston, TX, United States." } }, { "@type": "Person", "name": "Zhiwen Li", "url": "https://questionsmedicales.fr/author/Zhiwen%20Li", "affiliation": { "@type": "Organization", "name": "National Health Commission Key Laboratory of Reproductive Health, Department of Epidemiology and Biostatistics, Institute of Reproductive and Child Health, School of Public Health, Peking University Health Science Center, Beijing, China." } }, { "@type": "Person", "name": "Lei Jin", "url": "https://questionsmedicales.fr/author/Lei%20Jin", "affiliation": { "@type": "Organization", "name": "National Health Commission Key Laboratory of Reproductive Health, Department of Epidemiology and Biostatistics, Institute of Reproductive and Child Health, School of Public Health, Peking University Health Science Center, Beijing, China." } }, { "@type": "Person", "name": "Linlin Wang", "url": "https://questionsmedicales.fr/author/Linlin%20Wang", "affiliation": { "@type": "Organization", "name": "National Health Commission Key Laboratory of Reproductive Health, Department of Epidemiology and Biostatistics, Institute of Reproductive and Child Health, School of Public Health, Peking University Health Science Center, Beijing, China." } }, { "@type": "Person", "name": "Aiguo Ren", "url": "https://questionsmedicales.fr/author/Aiguo%20Ren", "affiliation": { "@type": "Organization", "name": "National Health Commission Key Laboratory of Reproductive Health, Department of Epidemiology and Biostatistics, Institute of Reproductive and Child Health, School of Public Health, Peking University Health Science Center, Beijing, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: A Multicenter Retrospective Study.", "datePublished": "2023-06-19", "url": "https://questionsmedicales.fr/article/37343766", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.modpat.2023.100241" } }, { "@type": "ScholarlyArticle", "name": "Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer - Controversies and Standards in Healthcare.", "datePublished": "2023-05-23", "url": "https://questionsmedicales.fr/article/37614683", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1055/a-2073-1887" } }, { "@type": "ScholarlyArticle", "name": "Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial.", "datePublished": "2023-04-03", "url": "https://questionsmedicales.fr/article/37022687", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1001/jamanetworkopen.2023.5822" } }, { "@type": "ScholarlyArticle", "name": "Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be identified via initial imaging.", "datePublished": "2023-03-23", "url": "https://questionsmedicales.fr/article/36959222", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-023-31051-7" } }, { "@type": "ScholarlyArticle", "name": "Hypofractionated whole breast irradiation in association with hypofractionated or normofractionated boost to the tumor bed in early breast cancer: tolerance and efficacy analysis.", "datePublished": "2023-03-22", "url": "https://questionsmedicales.fr/article/36947361", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12094-023-03124-6" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Malformations et maladies congénitales, héréditaires et néonatales", "item": "https://questionsmedicales.fr/mesh/D009358" }, { "@type": "ListItem", "position": 3, "name": "Malformations", "item": "https://questionsmedicales.fr/mesh/D000013" }, { "@type": "ListItem", "position": 4, "name": "Malformations du système nerveux", "item": "https://questionsmedicales.fr/mesh/D009421" }, { "@type": "ListItem", "position": 5, "name": "Anomalies du tube neural", "item": "https://questionsmedicales.fr/mesh/D009436" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Anomalies du tube neural - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Anomalies du tube neural", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-11", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Anomalies du tube neural", "description": "Comment diagnostique-t-on une anomalie du tube neural ?\nQuels examens sont utilisés pour confirmer le diagnostic ?\nÀ quel moment le diagnostic est-il généralement posé ?\nQuels signes échographiques indiquent une anomalie ?\nPeut-on détecter ces anomalies après la naissance ?", "url": "https://questionsmedicales.fr/mesh/D009436?mesh_terms=Early+Detection+of+Cancer&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Anomalies du tube neural", "description": "Quels sont les symptômes d'une anomalie du tube neural ?\nLes anomalies du tube neural causent-elles des douleurs ?\nComment se manifestent les anomalies après la naissance ?\nLes anomalies du tube neural affectent-elles la cognition ?\nY a-t-il des signes visibles à la naissance ?", "url": "https://questionsmedicales.fr/mesh/D009436?mesh_terms=Early+Detection+of+Cancer&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Anomalies du tube neural", "description": "Comment prévenir les anomalies du tube neural ?\nQuel est le dosage recommandé d'acide folique ?\nY a-t-il d'autres mesures préventives ?\nLes vaccinations influencent-elles le risque ?\nLes antécédents familiaux augmentent-ils le risque ?", "url": "https://questionsmedicales.fr/mesh/D009436?mesh_terms=Early+Detection+of+Cancer&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Anomalies du tube neural", "description": "Quels traitements sont disponibles pour ces anomalies ?\nLa chirurgie est-elle toujours nécessaire ?\nQuels types de rééducation sont recommandés ?\nY a-t-il des traitements médicamenteux ?\nComment le soutien psychologique aide-t-il ?", "url": "https://questionsmedicales.fr/mesh/D009436?mesh_terms=Early+Detection+of+Cancer&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Anomalies du tube neural", "description": "Quelles complications peuvent survenir ?\nLes anomalies du tube neural peuvent-elles entraîner des décès ?\nComment les complications affectent-elles la qualité de vie ?\nY a-t-il des complications à long terme ?\nLes complications sont-elles évitables ?", "url": "https://questionsmedicales.fr/mesh/D009436?mesh_terms=Early+Detection+of+Cancer&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Anomalies du tube neural", "description": "Quels sont les principaux facteurs de risque ?\nL'âge maternel influence-t-il le risque ?\nLes médicaments peuvent-ils augmenter le risque ?\nLe poids maternel joue-t-il un rôle ?\nLes infections pendant la grossesse sont-elles un risque ?", "url": "https://questionsmedicales.fr/mesh/D009436?mesh_terms=Early+Detection+of+Cancer&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on une anomalie du tube neural ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par échographie prénatale et tests génétiques." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour confirmer le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'amniocentèse et l'échographie 3D peuvent confirmer les anomalies." } }, { "@type": "Question", "name": "À quel moment le diagnostic est-il généralement posé ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic est souvent posé entre la 12e et la 20e semaine de grossesse." } }, { "@type": "Question", "name": "Quels signes échographiques indiquent une anomalie ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme l'absence de boîte crânienne ou des malformations vertébrales." } }, { "@type": "Question", "name": "Peut-on détecter ces anomalies après la naissance ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines anomalies peuvent être détectées par examen physique après la naissance." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une anomalie du tube neural ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des problèmes neurologiques, des malformations crâniennes et des troubles moteurs." } }, { "@type": "Question", "name": "Les anomalies du tube neural causent-elles des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les douleurs ne sont pas typiques, mais des complications peuvent entraîner des douleurs." } }, { "@type": "Question", "name": "Comment se manifestent les anomalies après la naissance ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent se manifester par des difficultés motrices et des retards de développement." } }, { "@type": "Question", "name": "Les anomalies du tube neural affectent-elles la cognition ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent affecter la cognition, selon la gravité et le type d'anomalie." } }, { "@type": "Question", "name": "Y a-t-il des signes visibles à la naissance ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des signes comme une hernie spinale ou des malformations crâniennes peuvent être visibles." } }, { "@type": "Question", "name": "Comment prévenir les anomalies du tube neural ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prise d'acide folique avant et pendant la grossesse réduit le risque." } }, { "@type": "Question", "name": "Quel est le dosage recommandé d'acide folique ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Un dosage de 400 à 800 microgrammes par jour est recommandé pour les femmes enceintes." } }, { "@type": "Question", "name": "Y a-t-il d'autres mesures préventives ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Éviter l'alcool et le tabac, et gérer les maladies chroniques sont également importants." } }, { "@type": "Question", "name": "Les vaccinations influencent-elles le risque ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Certaines vaccinations sont recommandées pour protéger la santé maternelle et fœtale." } }, { "@type": "Question", "name": "Les antécédents familiaux augmentent-ils le risque ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux d'anomalies du tube neural peuvent augmenter le risque." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour ces anomalies ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la chirurgie, la rééducation et le soutien psychologique." } }, { "@type": "Question", "name": "La chirurgie est-elle toujours nécessaire ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Non, la nécessité de la chirurgie dépend de la gravité de l'anomalie." } }, { "@type": "Question", "name": "Quels types de rééducation sont recommandés ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La rééducation physique et l'orthophonie sont souvent recommandées." } }, { "@type": "Question", "name": "Y a-t-il des traitements médicamenteux ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments peuvent être prescrits pour gérer les symptômes associés." } }, { "@type": "Question", "name": "Comment le soutien psychologique aide-t-il ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Il aide les familles à faire face aux défis émotionnels et pratiques des anomalies." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des infections, des troubles neurologiques et des problèmes de mobilité." } }, { "@type": "Question", "name": "Les anomalies du tube neural peuvent-elles entraîner des décès ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines anomalies graves peuvent entraîner des décès néonatals." } }, { "@type": "Question", "name": "Comment les complications affectent-elles la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent limiter les activités quotidiennes et nécessiter des soins constants." } }, { "@type": "Question", "name": "Y a-t-il des complications à long terme ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications à long terme peuvent inclure des troubles cognitifs et moteurs." } }, { "@type": "Question", "name": "Les complications sont-elles évitables ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être évitées par un suivi médical approprié." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, le diabète et la carence en acide folique." } }, { "@type": "Question", "name": "L'âge maternel influence-t-il le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les femmes de plus de 35 ans ont un risque accru d'anomalies du tube neural." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils augmenter le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certains médicaments, comme les antiépileptiques, peuvent augmenter le risque." } }, { "@type": "Question", "name": "Le poids maternel joue-t-il un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'obésité maternelle est un facteur de risque pour les anomalies du tube neural." } }, { "@type": "Question", "name": "Les infections pendant la grossesse sont-elles un risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections, comme la rubéole, peuvent augmenter le risque d'anomalies." } } ] } ] }

Sources (10000 au total)

Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial.

Trastuzumab has been the standard of care for the treatment of patients with ERBB2-positive breast cancer; however, cardiac events have been reported. This long-term follow-up study provides clinical ... To compare cardiac safety and efficacy between SB3 and TRZ for patients with ERBB2-positive early or locally advanced breast cancer after up to 6 years of follow-up.... This prespecified secondary analysis of a randomized clinical trial, conducted from April 2016 to January 2021, included patients with ERBB2-positive early or locally advanced breast cancer from a mul... In the original trial, patients were randomized to either SB3 or TRZ with concomitant neoadjuvant chemotherapy for 8 cycles (4 cycles of docetaxel followed by 4 cycles of fluorouracil, epirubicin, and... The primary outcomes were the incidence of symptomatic congestive heart failure and asymptomatic, significant decrease in left ventricular ejection fraction (LVEF). The secondary outcomes were event-f... A total of 538 female patients were included (median age, 51 years [range, 22-65 years]). Baseline characteristics were comparable between the SB3 and TRZ groups. Cardiac safety was monitored for 367 ... In this secondary analysis of a randomized clinical trial, SB3 demonstrated cardiac safety and survival comparable to those of TRZ after up to 6 years of follow-up in patients with ERBB2-positive earl... ClinicalTrials.gov Identifier: NCT02771795....

Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be identified via initial imaging.

Molecular assessment using circulating tumor DNA (ctDNA) has not been well-defined. We recruited 61 pancreatic cancer (PC) patients who underwent initial computed tomography (CT) imaging study during ...

Hypofractionated whole breast irradiation in association with hypofractionated or normofractionated boost to the tumor bed in early breast cancer: tolerance and efficacy analysis.

The boost to the tumor bed improves local control in breast cancer and it is an important part of the breast conserving therapy. However, information about the use of a hypofractionated boost is spars... A total of 96 women with early breast cancer undergoing breast-conserving surgery and hypofractionated whole breast irradiation (WBI) were retrospectively analyzed divided into hypofractionated boost ... The median follow-up was 49.5 months (26-67). Median age was 57 years (36-82). Sixty-six patients (68.7%) were younger than 60 years at the time of boost and 30 (31.2%) were older than 60 years who re... Hypofractionated WBI associated with HB treatment is a viable option in the management of conservative breast therapy given the good tolerance and similar local control....

Analysis of risk factors for lymph node metastasis and prognosis study in patients with early gastric cancer: A SEER data-based study.

Lymph node status is an important factor in determining the prognosis of patients with early gastric cancer (EGC) and preoperative diagnosis of lymph node metastasis (LNM) has some limitations. This s... Clinicopathological data of EGC patients was collected from the public Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate logistic regression was used to identify... A total of 3993 EGC patients were randomly allocated to a training cohort (n=2797) and a validation cohort (n=1196). An external cohort of 106 patients from the Second Hospital of Lanzhou University w... In this study, we identified risk factors and independent prognostic factors for the development of LNM in EGC patients, and developed a relatively accurate model to predict the development of LNM in ...

Comparison of the effects of endoscopic submucosal dissection and laparoscopic distal radical surgery on the rehabilitation and quality of life of patients with early gastric cancer.

This study was designed to compare the effects of endoscopic submucosal dissection (ESD) and laparoscopic distal radical surgery (LDRS) on patient rehabilitation and quality of life (QoL) in patients ... The clinical data of 52 patients with early GC admitted to Wuhan Union Hospital from January 2018 to December 2020 were retrospectively analyzed. Among them, 32 patients who underwent LDRS were assign... The laparoscopic group showed a significantly lower complete resection rate than the endoscopic group (P=0.030). The endoscopic group experienced notably less intraoperative blood loss and operation t... With significantly better efficacy than that of LDRS, ESD is beneficial to postoperative rehabilitation and can improve the QoL of patients, and both schemes cause no significant effect on the recurre...

Establishment and validation of a multigene model to predict the risk of relapse in hormone receptor-positive early-stage Chinese breast cancer patients.

Breast cancer patients who are positive for hormone receptor typically exhibit a favorable prognosis. It is controversial whether chemotherapy is necessary for them after surgery. Our study aimed to e... In this study, differentially expressed genes (DEGs) were identified between relapse and nonrelapse breast cancer groups based on RNA sequencing. Gene set enrichment analysis (GSEA) was performed to i... A total of 234 out of 487 patients were enrolled in this study, and 1588 DEGs were identified between the relapse and nonrelapse groups. GSEA results showed that immune-related pathways were enriched ... A multigene model was established from RNA-sequencing data to direct risk classification and predict relapse of hormone receptor-positive breast cancer in Chinese patients. Utilization of the model co...

Impact of age on indication for chemotherapy in early breast cancer patients: results from 104 German institutions from 2008 to 2017.

Today, the decision to treat patients with chemotherapy for early breast cancer (EBC) is made based on the patient's individual risk stratification and tumor biology. In cases with chemotherapy indica... The study separately analyzed chemotherapy use among six age cohorts of EBC patients who had been treated at 104 German breast units between January 2008 and December 2017.... In total, 124,084 patients were included, 46,279 (37.3%) of whom had received chemotherapy. For 44,765 of these cases, detailed information on treatment was available. Within this cohort, chemotherapy... The data from the nationwide German cohort reveal relevant age-dependent discrepancies concerning the use of chemotherapy for EBC....